Allison-Honjo Nobel 2018: anti-CTLA-4 (Ipilimumab 2011) + anti-PD-1 (Pembrolizumab/Nivolumab 2014) checkpoint inhibitors restore anti-tumor T-cell response; revolutionized melanoma + lung cancer.
Allison-Honjo Nobel 2018: anti-CTLA-4 (Ipilimumab 2011) + anti-PD-1 (Pembrolizumab/Nivolumab 2014) checkpoint inhibitors restore anti-tumor T-cell response; revolutionized melanoma + lung cancer.